May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes
Apr 3, 2024, 13:35

Kefah Mokbel: Insights into the management of Leptomeningeal Disease and clinical outcomes

Kefah Mokbel, Chair of The Multidisciplinary Breast Cancer Program at London Breast Institute, shared on LinkedIn:

“Insights into the management of Leptomeningeal disease (LMD) and clinical outcomes:

I would like to add the following comments:

In ER-positive breast cancer, Abemaciclib should be considered the CDK4/6 inhibitor of choice due to its superior penetration through the blood-brain barrier (BBB).

Intrathecal therapy remains underutilized in both research and clinical management settings.

Lumbar puncture for direct genomics analysis is also underutilized and warrants further exploration.

The role of PD-1 and PD-L1 inhibitors in patients with PD-L1 positive disease deserves further discussion (response rates exceeds 30%).”

Proceed to the article.
Source: Kefah Mokbel/LinkedIn